3733-63-9

Basic information

• Product Name: Decloxizine
• Synonyms: 1-benzhydryl-4-(2-(2-hydroxyethoxy)ethyl)piperazine;decloxizine;DECLOXIZIN HYDROCHLORIDE;Decloxizine Base;decloxazine;2-[2-[4-(Diphenylmethyl)-1-piperazinyl]ethoxy]ethanol;UCB 1402;UCB-1402
• CAS NO: 3733-63-9
• Molecular Formula: C₂₁H₂₈N₂O₂
• Molecular Weight: 340.45922
• Product Categories: Pharmaceutical Intermediates
• Mol File: 3733-63-9.mol

Chemical Properties

• Boiling Point: 476.25°C (rough estimate)
• Flash Point: 239.5 °C
• Appearance: /
• Density: 1.1027 (rough estimate)
• Vapor Pressure: 9.93E-10mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 14.41±0.10(Predicted)
• CAS DataBase Reference: Decloxizine(CAS DataBase Reference)
• NIST Chemistry Reference: Decloxizine(3733-63-9)
• EPA Substance Registry System: Decloxizine(3733-63-9)

Safety Data

• Hazardous Substances Data: 3733-63-9(Hazardous Substances Data)

Usage

Uses

Decloxizine is a histamine 1 receptor antagonist. Hydroxyzine (H996500) impurity.

Safety Profile

Poison by intraperitoneal andintravenous routes. Moderately toxic by ingestion. Anexperimental teratogen. Other experimental reproductiveeffects. When heated to decomposition it emits toxicfumes of NOx.

InChI:InChI=1/C21H28N2O2/c24-16-18-25-17-15-22-11-13-23(14-12-22)21(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-10,21,24H,11-18H2

Upstream product

• 841-77-0 diphenylmethylpiperazine 
• 628-89-7 2-(2-Chloroethoxy)ethanol 

Downstream Products

• 227776-20-7 2-{2-[2-(4-diphenylmethyl-piperazin-1-yl)-ethoxy]-ethyl}-isoindolin-1,3-dione 

Relevant articles and documents

Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides

The invention relates to new piperazinyl-substituted pyridylalkane, alkene, and alkine acid amides substituted with saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to the general formula (I) as well as methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.

Condensed pyridazine derivatives, their production and use

A condensed pyridazine derivative which is useful as a pharmaceutical composition for preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria and prurigo.

NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES

A nose drop containing the compound (I) represented by the formula wherein Ar1 and Ar2 are each an aromatic group, Ar1 and Ar2 optionally form a condensed cyclic group together with the adjacent carbon atom, ring B is a nitrogen-containing heterocycle, X and Y are each a bond, an oxygen atom or S(O)p (p is 0 to 2), NR4 (R4 is H or a lower alkyl group) or a divalent linear lower hydrocarbon group optionally having substituents and containing 1 to 3 heteroatoms, A is N or CR7 (R7 is H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents), R1, R2 and R3 are each H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents, and R8 is H, a hydroxy group optionally substituted by a lower alkyl group or a carboxyl group, provided that the nitrogen-containing heterocycle represented by ring B is not a heterocycle represented by the formula wherein n is 0 - 1, or a salt thereof or a prodrug thereof, exhibits a superior prophylactic or therapeutic effect on allergic rhinitis and the like.

Condensed pyridazine derivatives, their production and use

The present invention provides a compound represented by the formula: wherein Ar1 and Ar2 are independently an aromatic group which may be substituted, and Ar1 and Ar2 may form a condensed cyclic group with an adjacent carbon atom; ring B is a nitrogen-containing heterocycle which may be substituted; X and Y are the same or different and are independently a bond, an oxygen atom, S(O)p (p is an integer of 0 ot 2), NR4 wherein R4 is a hydrogen atom or a lower alkyl group, or a bivalent linear lower hydrocarbon group which may contain 1 to 3 hetero atoms and the bivalent linear lower hydrocarbon group may be substituted; A is a nitrogen atom or CR7 wherein R7 is a hydrogen atom, a halogen atom, a hydrocarbon which may be substituted, an acyl group or a hydroxy group which may be substituted; R1, R2 and R3 are the same or different and are independently a hydrogen atom, a halogen atom, a hydrocarbon group which may be substituted, an acyl group or a hydroxy group which may be substituted; R8 is a hydrogen atom, a hydroxy group which may be substituted by a lower alkyl or a carboxyl group, or a salt thereof, which exhibits excellent anti-histaminic or eosinophil chemotaxis-inhibiting activities and is useful in treatment or prevention of asthma, allergic conjunctivitis, allergic rhinitis, chronic urticaria or atopic dermatitis.